Skip to main content

Jury Finds Roundup Was a Major Cause of Cancer in Plaintiff

Jury Finds Roundup Was a Major Cause of Cancer in Plaintiff

Jury Finds Roundup Was a Major Cause of Cancer in Plaintiff

Introduction

On Tuesday, March 19, as a major setback to Monsanto, the first phase of the closely watched Roundup trial concluded with the San Francisco federal jury affirming that Monsanto's weed killer was a substantial cause of cancer in a California man.

The unanimous verdict was given by five women and one man in favor of a 70-year old plaintiff after a week of deliberations. The jury rejected Monsanto's argument that there was no possibility to detect the cause of the plaintiff's non-Hodgkin's lymphoma (NHL). The bellwether trial, which began on February 25, was split into two phases; in the first phase, the jury was supposed to decide whether scientific studies support the conclusion that Roundup and its active component, glyphosate, can lead to NHL and whether glyphosate exposure was the reason for the plaintiff's cancer. Damages and other claims would be decided by the jury in the second phase. The plaintiff used Roundup products on his Sonoma County property between the 1980s and 2012. He was diagnosed with NHL in 2015. Though Monsanto strongly denies responsibility for the man's cancer, the second phase of the trial would determine whether the company was liable or not.

U.S. District Judge Vince Chhabria overlooks the Roundup lawsuits, which are consolidated into multidistrict litigation (MDL No. 2741; In Re: Roundup Products Liability Litigation) in the Northern District of California.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!